Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for RYTM

Stock Name	Rhythm Pharmaceuticals Inc
Ticker	RYTM(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US76243J1051
LEI	529900JPNWXQ8DPLA551

Show aggregate RYTM holdings

News associated with RYTM

FDA Accepts Rhythm Pharma' SNDA For Setmelanotide To Treat Acquired Hypothalamic Obesity: (RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application or sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypotha - 2025-08-20 22:52:50
Chicago Partners Investment Group LLC Sells 186 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Chicago Partners Investment Group LLC reduced its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 5.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,510 shares of the company’s stock after selling 186 shares during the period. Chicago Partners Investment Group LLC’s holdings […] - 2025-08-13 05:18:50
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $91.93: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned an average rating of “Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts […] - 2025-08-04 02:26:49
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Holdings Lifted by Victory Capital Management Inc.: Victory Capital Management Inc. lifted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,326 shares of the company’s stock after acquiring an additional 174 shares during the […] - 2025-08-01 05:01:17
Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to “Hold”: Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. RYTM has been the subject of several other reports. Oppenheimer boosted their target price on Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the company an […] - 2025-07-28 04:00:47
Bank of New York Mellon Corp Sells 1,661 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Bank of New York Mellon Corp reduced its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.1% in the first quarter, HoldingsChannel reports. The firm owned 146,585 shares of the company’s stock after selling 1,661 shares during the period. Bank of New York Mellon Corp’s holdings in Rhythm Pharmaceuticals were worth $7,765,000 at […] - 2025-07-23 04:34:46
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says: Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective lifted by Canaccord Genuity Group from $92.00 to $105.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 17.71% from the stock’s current price. Several […] - 2025-07-20 05:22:52
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells $308,222.75 in Stock: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CAO Christopher Paul German sold 3,817 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $80.75, for a total transaction of $308,222.75. Following the transaction, the chief accounting officer directly owned 922 shares of the […] - 2025-07-14 06:10:46
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High Following Analyst Upgrade: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $76.00 to $110.00. Oppenheimer currently has an outperform rating on the stock. Rhythm Pharmaceuticals traded as high as $89.05 and last traded at $89.00, with […] - 2025-07-11 02:50:53
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Analyst Upgrade: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price gapped up prior to trading on Wednesday after Needham & Company LLC raised their price target on the stock from $72.00 to $95.00. The stock had previously closed at $65.14, but opened at $76.75. Needham & Company LLC currently has a buy rating on the […] - 2025-07-10 02:19:11
Wednesday's ETF Movers: XBI, COPX: In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.7% on the day. Components of that ETF showing particular strength include shares of Rhythm Pharmaceuticals, up about 31.3% and shares of Capricor Therapeutics, up about 12.3% on the da - 2025-07-09 13:28:39
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of “Buy” by Brokerages: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned an average rating of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock […] - 2025-07-07 03:16:56
Avior Wealth Management LLC Acquires Shares of 4,589 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Avior Wealth Management LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 4,589 shares of the company’s stock, valued at approximately $243,000. Several other institutional investors and hedge funds have also bought and sold shares of the business. Assenagon Asset […] - 2025-06-24 04:52:55
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of “Buy” from Analysts: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has received a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Thirteen investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in […] - 2025-06-12 04:56:54
Analysts Forecast 16% Upside For The Holdings of SMLF: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:51:20
Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 76,084 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 76,084 shares of the company’s stock, valued at approximately $4,259,000. A number of other hedge funds and other institutional investors have also added to or reduced their […] - 2025-06-02 05:36:58
Nuveen Asset Management LLC Sells 972 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Nuveen Asset Management LLC decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,903 shares of the company’s stock after selling 972 shares during […] - 2025-05-29 05:36:56
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,156 shares of the company’s stock after buying an additional 654 shares during […] - 2025-05-23 05:32:53
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $75.38: Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on […] - 2025-05-23 04:30:49
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by BNP Paribas Financial Markets: BNP Paribas Financial Markets boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 491.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,249 shares of the company’s stock after purchasing an additional 70,824 shares during the period. BNP […] - 2025-05-14 06:42:59
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Comerica Bank: Comerica Bank lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 17,113 shares of the company’s stock after selling 447 shares during the period. Comerica Bank’s holdings in Rhythm Pharmaceuticals were worth $958,000 as of its most recent filing with the […] - 2025-05-13 06:00:54
Stifel Financial Corp Has $1.09 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Stifel Financial Corp decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,516 shares of the company’s stock after selling 326 shares during the quarter. Stifel Financial Corp’s holdings in […] - 2025-05-09 05:27:01
First Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): First Trust Advisors LP grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 118,337 shares of the company’s stock after buying an additional 47,575 shares during the period. First Trust Advisors LP owned 0.19% of […] - 2025-04-30 06:01:00
Legal & General Group Plc Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Legal & General Group Plc decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 7.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,803 shares of the company’s stock after selling 4,244 shares during the period. Legal & General […] - 2025-04-24 05:07:03
Invesco Ltd. Has $16.95 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Invesco Ltd. grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 14.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 302,846 shares of the company’s stock after purchasing an additional 38,429 shares during the period. Invesco Ltd.’s holdings in Rhythm Pharmaceuticals were worth $16,953,000 at the end of the […] - 2025-04-21 04:44:46
Trexquant Investment LP Takes $437,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Trexquant Investment LP bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 7,798 shares of the company’s stock, valued at approximately $437,000. A number of other large investors have also recently added to or reduced their stakes in RYTM. SRS Capital Advisors […] - 2025-04-13 05:31:02
Rhythm Pharmaceuticals (NASDAQ:RYTM) Raised to Buy at Bank of America: Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm presently has a $63.00 price objective on the stock. Bank of America‘s price objective points to a […] - 2025-04-09 02:52:50
Norges Bank Acquires New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Norges Bank bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 205,649 shares of the company’s stock, valued at approximately $11,512,000. Norges Bank owned approximately 0.33% […] - 2025-04-08 04:48:51
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00: Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price target upped by Wells Fargo & Company from $80.00 to $91.00 in a research note published on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other research firms have also recently issued reports on RYTM. Morgan Stanley restated […] - 2025-04-08 02:52:50
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up After Analyst Upgrade: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price gapped up before the market opened on Monday after Wells Fargo & Company raised their price target on the stock from $80.00 to $91.00. The stock had previously closed at $46.95, but opened at $48.33. Wells Fargo & Company currently has an overweight rating on […] - 2025-04-08 02:12:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) RYTM holdings

Date	Number of RYTM Shares Held	Base Market Value of RYTM Shares	Local Market Value of RYTM Shares	Change in RYTM Shares Held	Change in RYTM Base Value	Current Price per RYTM Share Held	Previous Price per RYTM Share Held
2025-12-03 (Wednesday)	46,730	USD 4,889,360	USD 4,889,360	0	USD 151,405	USD 104.63	USD 101.39
2025-12-02 (Tuesday)	46,730	USD 4,737,955	USD 4,737,955	1,665	USD 4,327	USD 101.39	USD 105.04
2025-12-01 (Monday)	45,065	USD 4,733,628	USD 4,733,628	0	USD -182,513	USD 105.04	USD 109.09
2025-11-28 (Friday)	45,065	USD 4,916,141	USD 4,916,141	111	USD 87,182	USD 109.09	USD 107.42
2025-11-27 (Thursday)	44,954	USD 4,828,959	USD 4,828,959	0	USD 0	USD 107.42	USD 107.42
2025-11-26 (Wednesday)	44,954	USD 4,828,959	USD 4,828,959	333	USD -23,575	USD 107.42	USD 108.75
2025-11-25 (Tuesday)	44,621	USD 4,852,534	USD 4,852,534	555	USD 155,980	USD 108.75	USD 106.58
2025-11-24 (Monday)	44,066	USD 4,696,554	USD 4,696,554	111	USD 224,572	USD 106.58	USD 101.74
2025-11-21 (Friday)	43,955	USD 4,471,982	USD 4,471,982	0	USD 47,472	USD 101.74	USD 100.66
2025-11-20 (Thursday)	43,955	USD 4,424,510	USD 4,424,510	-444	USD -155,247	USD 100.66	USD 103.15
2025-11-19 (Wednesday)	44,399	USD 4,579,757	USD 4,579,757	111	USD 128,370	USD 103.15	USD 100.51
2025-11-18 (Tuesday)	44,288	USD 4,451,387	USD 4,451,387	666	USD 59,088	USD 100.51	USD 100.69
2025-11-17 (Monday)	43,622	USD 4,392,299	USD 4,392,299	222	USD 77,905	USD 100.69	USD 99.41

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RYTM by Blackrock for IE00BDZVHG35

Show aggregate share trades of RYTM

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 1,665 101.390* 70.20
2025-11-28 BUY 111 109.090* 69.83
2025-11-26 BUY 333 109.735 104.420 104.951 USD 34,949 69.46
2025-11-25 BUY 555 109.880 106.900 107.198 USD 59,495 69.26
2025-11-24 BUY 111 107.000 101.750 102.275 USD 11,353 69.08
2025-11-20 SELL -444 100.660* 68.75 Profit of 30,525 on sale
2025-11-19 BUY 111 103.150* 68.57
2025-11-18 BUY 666 100.510* 68.41
2025-11-17 BUY 222 100.690* 68.24
2025-11-14 BUY 111 102.125 95.460 96.126 USD 10,670 68.08
2025-11-12 BUY 111 97.920* 67.78
2025-11-10 BUY 110 101.050 96.100 96.595 USD 10,625 67.45
2025-11-06 BUY 110 98.490* 67.11
2025-11-04 BUY 111 112.660 102.100 103.156 USD 11,450 66.73
2025-10-30 BUY 555 116.000 110.450 111.005 USD 61,608 65.97
2025-10-29 BUY 548 113.890 114.590 114.520 USD 62,757 65.70
2025-10-22 SELL -440 109.170 109.745 109.688 USD -48,263 64.42 Loss of -19,916 on sale
2025-10-20 BUY 220 112.390 113.560 113.443 USD 24,957 63.90
2025-10-17 BUY 549 110.280 111.720 111.576 USD 61,255 63.63
2025-10-15 BUY 872 109.350 109.720 109.683 USD 95,644 63.37
2025-10-03 BUY 770 99.020 102.790 102.413 USD 78,858 62.91
2025-10-02 BUY 110 97.230 99.830 99.570 USD 10,953 62.71
2025-09-30 BUY 220 100.990 103.070 102.862 USD 22,630 62.26
2025-09-26 BUY 220 99.160 100.070 99.979 USD 21,995 61.80
2025-09-25 BUY 220 99.140 99.600 99.554 USD 21,902 61.57
2025-09-18 BUY 109 98.540 98.880 98.846 USD 10,774 61.35
2025-09-17 BUY 330 96.100 97.895 97.715 USD 32,246 61.13
2025-09-11 SELL -110 97.920 102.460 102.006 USD -11,221 60.69 Loss of -4,545 on sale
2025-09-10 BUY 220 100.270 102.110 101.926 USD 22,424 60.44
2025-07-17 SELL -220 90.680 92.080 91.940 USD -20,227 59.61 Loss of -7,113 on sale
2025-07-16 BUY 364 91.440 92.135 92.066 USD 33,512 59.40
2025-07-11 SELL -872 86.700 90.360 89.994 USD -78,475 58.83 Loss of -27,177 on sale
2025-07-02 BUY 5,995 66.920 67.750 67.667 USD 405,664 58.31
2025-06-25 BUY 218 62.290 63.600 63.469 USD 13,836 58.20
2025-06-20 BUY 1,110 61.990 62.360 62.323 USD 69,179 58.11
2025-06-11 BUY 210 64.840 67.265 67.022 USD 14,075 57.87
2025-06-10 BUY 210 67.370 67.740 67.703 USD 14,218 57.80
2025-06-04 SELL -105 64.395 66.510 66.299 USD -6,961 57.53 Loss of -921 on sale
2025-04-23 BUY 105 59.840 61.780 61.586 USD 6,467 56.19
2025-04-10 SELL -840 57.830 59.160 59.027 USD -49,583 55.75 Loss of -2,750 on sale
2025-04-08 SELL -105 57.730 63.110 62.572 USD -6,570 55.68 Loss of -724 on sale
2025-04-07 SELL -105 54.960 55.900 55.806 USD -5,860 55.69 Loss of -12 on sale
2025-04-04 SELL -525 46.950 49.055 48.845 USD -25,643 55.79 Profit of 3,646 on sale
2025-04-01 BUY 918 50.000 54.670 54.203 USD 49,758 55.91
2025-03-31 SELL -309 52.970 53.410 53.366 USD -16,490 55.94 Profit of 796 on sale
2025-03-21 BUY 2,177 52.040 54.450 54.209 USD 118,013 56.13
2025-03-14 SELL -1,536 50.970 52.050 51.942 USD -79,783 56.35 Profit of 6,772 on sale
2025-03-07 SELL -192 50.790 52.350 52.194 USD -10,021 56.82 Profit of 888 on sale
2025-03-04 SELL -96 53.220 53.500 53.472 USD -5,133 57.02 Profit of 340 on sale
2025-02-25 BUY 192 51.030 55.010 54.612 USD 10,486 57.37
2025-02-19 SELL -96 58.000 58.240 58.216 USD -5,589 57.43 Loss of -76 on sale
2025-02-13 BUY 288 57.560 58.645 58.537 USD 16,859 57.45
2025-02-12 BUY 96 57.640 57.700 57.694 USD 5,539 57.45
2025-02-11 BUY 384 57.580 58.160 58.102 USD 22,311 57.44
2024-12-30 SELL -3,141 56.340 56.840 56.790 USD -178,377 56.89 Profit of 316 on sale
2024-11-18 SELL -1,572 58.500 58.640 58.626 USD -92,160 53.69 Loss of -7,760 on sale
2024-11-08 SELL -105 67.330 67.610 67.582 USD -7,096 51.97 Loss of -1,639 on sale
2024-10-21 SELL -105 50.190 52.000 51.819 USD -5,441 0.00 Loss of -5,441 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	1,665			101.390*		70.20
2025-11-28	BUY	111			109.090*		69.83
2025-11-26	BUY	333	109.735	104.420	104.951	USD 34,949	69.46
2025-11-25	BUY	555	109.880	106.900	107.198	USD 59,495	69.26
2025-11-24	BUY	111	107.000	101.750	102.275	USD 11,353	69.08
2025-11-20	SELL	-444			100.660*		68.75 Profit of 30,525 on sale
2025-11-19	BUY	111			103.150*		68.57
2025-11-18	BUY	666			100.510*		68.41
2025-11-17	BUY	222			100.690*		68.24
2025-11-14	BUY	111	102.125	95.460	96.126	USD 10,670	68.08
2025-11-12	BUY	111			97.920*		67.78
2025-11-10	BUY	110	101.050	96.100	96.595	USD 10,625	67.45
2025-11-06	BUY	110			98.490*		67.11
2025-11-04	BUY	111	112.660	102.100	103.156	USD 11,450	66.73
2025-10-30	BUY	555	116.000	110.450	111.005	USD 61,608	65.97
2025-10-29	BUY	548	113.890	114.590	114.520	USD 62,757	65.70
2025-10-22	SELL	-440	109.170	109.745	109.688	USD -48,263	64.42 Loss of -19,916 on sale
2025-10-20	BUY	220	112.390	113.560	113.443	USD 24,957	63.90
2025-10-17	BUY	549	110.280	111.720	111.576	USD 61,255	63.63
2025-10-15	BUY	872	109.350	109.720	109.683	USD 95,644	63.37
2025-10-03	BUY	770	99.020	102.790	102.413	USD 78,858	62.91
2025-10-02	BUY	110	97.230	99.830	99.570	USD 10,953	62.71
2025-09-30	BUY	220	100.990	103.070	102.862	USD 22,630	62.26
2025-09-26	BUY	220	99.160	100.070	99.979	USD 21,995	61.80
2025-09-25	BUY	220	99.140	99.600	99.554	USD 21,902	61.57
2025-09-18	BUY	109	98.540	98.880	98.846	USD 10,774	61.35
2025-09-17	BUY	330	96.100	97.895	97.715	USD 32,246	61.13
2025-09-11	SELL	-110	97.920	102.460	102.006	USD -11,221	60.69 Loss of -4,545 on sale
2025-09-10	BUY	220	100.270	102.110	101.926	USD 22,424	60.44
2025-07-17	SELL	-220	90.680	92.080	91.940	USD -20,227	59.61 Loss of -7,113 on sale
2025-07-16	BUY	364	91.440	92.135	92.066	USD 33,512	59.40
2025-07-11	SELL	-872	86.700	90.360	89.994	USD -78,475	58.83 Loss of -27,177 on sale
2025-07-02	BUY	5,995	66.920	67.750	67.667	USD 405,664	58.31
2025-06-25	BUY	218	62.290	63.600	63.469	USD 13,836	58.20
2025-06-20	BUY	1,110	61.990	62.360	62.323	USD 69,179	58.11
2025-06-11	BUY	210	64.840	67.265	67.022	USD 14,075	57.87
2025-06-10	BUY	210	67.370	67.740	67.703	USD 14,218	57.80
2025-06-04	SELL	-105	64.395	66.510	66.299	USD -6,961	57.53 Loss of -921 on sale
2025-04-23	BUY	105	59.840	61.780	61.586	USD 6,467	56.19
2025-04-10	SELL	-840	57.830	59.160	59.027	USD -49,583	55.75 Loss of -2,750 on sale
2025-04-08	SELL	-105	57.730	63.110	62.572	USD -6,570	55.68 Loss of -724 on sale
2025-04-07	SELL	-105	54.960	55.900	55.806	USD -5,860	55.69 Loss of -12 on sale
2025-04-04	SELL	-525	46.950	49.055	48.845	USD -25,643	55.79 Profit of 3,646 on sale
2025-04-01	BUY	918	50.000	54.670	54.203	USD 49,758	55.91
2025-03-31	SELL	-309	52.970	53.410	53.366	USD -16,490	55.94 Profit of 796 on sale
2025-03-21	BUY	2,177	52.040	54.450	54.209	USD 118,013	56.13
2025-03-14	SELL	-1,536	50.970	52.050	51.942	USD -79,783	56.35 Profit of 6,772 on sale
2025-03-07	SELL	-192	50.790	52.350	52.194	USD -10,021	56.82 Profit of 888 on sale
2025-03-04	SELL	-96	53.220	53.500	53.472	USD -5,133	57.02 Profit of 340 on sale
2025-02-25	BUY	192	51.030	55.010	54.612	USD 10,486	57.37
2025-02-19	SELL	-96	58.000	58.240	58.216	USD -5,589	57.43 Loss of -76 on sale
2025-02-13	BUY	288	57.560	58.645	58.537	USD 16,859	57.45
2025-02-12	BUY	96	57.640	57.700	57.694	USD 5,539	57.45
2025-02-11	BUY	384	57.580	58.160	58.102	USD 22,311	57.44
2024-12-30	SELL	-3,141	56.340	56.840	56.790	USD -178,377	56.89 Profit of 316 on sale
2024-11-18	SELL	-1,572	58.500	58.640	58.626	USD -92,160	53.69 Loss of -7,760 on sale
2024-11-08	SELL	-105	67.330	67.610	67.582	USD -7,096	51.97 Loss of -1,639 on sale
2024-10-21	SELL	-105	50.190	52.000	51.819	USD -5,441	0.00 Loss of -5,441 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RYTM

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	57,758	0	112,124	51.5%
2025-09-18	79,829	0	132,267	60.4%
2025-09-17	94,811	0	142,281	66.6%
2025-09-16	69,294	20	105,418	65.7%
2025-09-15	49,993	495	130,675	38.3%
2025-09-12	91,089	428	207,398	43.9%
2025-09-11	102,976	4,654	284,277	36.2%
2025-09-10	112,334	5,431	192,887	58.2%
2025-09-09	81,316	0	146,467	55.5%
2025-09-08	107,071	0	320,026	33.5%
2025-09-05	85,282	21	165,032	51.7%
2025-09-04	63,034	1,268	179,406	35.1%
2025-09-03	93,856	4,725	232,517	40.4%
2025-09-02	118,650	1,127	276,515	42.9%
2025-08-29	52,459	33	140,594	37.3%
2025-08-28	88,661	500	177,301	50.0%
2025-08-27	34,370	0	144,198	23.8%
2025-08-26	35,895	3,580	182,877	19.6%
2025-08-25	52,322	0	141,150	37.1%
2025-08-22	134,285	3,024	254,451	52.8%
2025-08-21	237,643	249	345,618	68.8%
2025-08-20	158,685	1,343	190,449	83.3%
2025-08-19	59,925	178	94,092	63.7%
2025-08-18	74,030	3,694	131,506	56.3%
2025-08-15	67,448	4,106	159,635	42.3%
2025-08-14	82,228	50	225,054	36.5%
2025-08-13	118,492	6,021	264,483	44.8%
2025-08-12	77,184	326	156,479	49.3%
2025-08-11	104,452	1,770	229,181	45.6%
2025-08-08	104,620	3,964	349,552	29.9%
2025-08-07	118,634	22,554	179,498	66.1%
2025-08-06	128,926	0	232,034	55.6%
2025-08-05	150,641	988	242,998	62.0%
2025-08-04	113,562	539	192,790	58.9%
2025-08-01	162,238	522	245,736	66.0%
2025-07-31	107,060	0	186,426	57.4%
2025-07-30	74,133	23	152,135	48.7%
2025-07-29	84,977	139	138,584	61.3%
2025-07-28	90,165	3	232,097	38.8%
2025-07-25	66,761	574	128,310	52.0%
2025-07-24	66,075	215	173,150	38.2%
2025-07-23	113,281	0	215,587	52.5%
2025-07-22	96,067	0	222,059	43.3%
2025-07-21	78,360	17	228,068	34.4%
2025-07-18	67,969	252	244,271	27.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE